Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21852720 | 0.88 | L3MBTL1 (0.64) | L3MBTL1ALDH1A1KDM4EKMT2AAKR1C3 | |
| SCHEMBL14197088 | 0.84 | KMT2A (0.59) | ALDH1A1KMT2AGAAMAPTGFER | |
| SCHEMBL30862679 | 0.83 | MAPT (0.67) | L3MBTL1ALDH1A1KDM4EKMT2AMAPK1 | |
| SCHEMBL632352 | 0.82 | L3MBTL1 (0.73) | L3MBTL1ALDH1A1KDM4EAKR1C3MAPK1 | |
| SCHEMBL4182066 | 0.82 | L3MBTL1 (0.73) | L3MBTL1ALDH1A1KDM4EKMT2AAKR1C3 | |
| SCHEMBL14586642 | 0.82 | POLB (0.59) | ALDH1A1KDM4EKMT2AAKR1C3GAA | |
| SCHEMBL12155872 | 0.82 | MAPT (0.59) | ALDH1A1KDM4EKMT2AGAAMAPT | |
| Hydrochloric Acid SCHEMBL6981966 | 0.81 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1KDM4EKMT2AAKR1C3 | |
| SCHEMBL23544884 | 0.81 | PANK3 (0.57) | L3MBTL1ALDH1A1KDM4EKMT2AMAPK1 | |
| SCHEMBL189134 | 0.81 | GFER (0.68) | L3MBTL1ALDH1A1KDM4EKMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249081-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN AND SCREENING METHODS THEREFOR | ACADIA PHARMACEUTICALS INC. | 2008-10-09 | — | — | US | disclosed |
| US-7354919-B2 | Isoxazole compositions useful as inhibitors of ERK | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CAO JINGRONG | 2007-11-15 | — | — | US | disclosed |
| US-7253187-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-07 | — | — | US | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAPKAPK2 | L3MBTL1 1804/4885ALDH1A1 3899/4885KDM4E 4090/4885 |
| US-20080249081-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN AND SCREENING METHODS THEREFOR | MRGPRX2, MRGPRX4, MRGPRX1 | L3MBTL1 4240/4885ALDH1A1 2124/4885KDM4E 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.